Free Trial
ETR:BAYN

Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

Bayer Aktiengesellschaft logo
€24.74 +0.01 (+0.04%)
As of 05/30/2025

About Bayer Aktiengesellschaft Stock (ETR:BAYN)

Key Stats

Today's Range
€24.50
€24.91
50-Day Range
€19.47
€24.93
52-Week Range
€24.96
€44.28
Volume
4.27 million shs
Average Volume
N/A
Market Capitalization
$24.97 billion
P/E Ratio
N/A
Dividend Yield
0.44%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Receive BAYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BAYN Stock News Headlines

Bayer will Standort Frankfurt bis 2028 schließen
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
Bayer-Aktie: Was für ein Kracher!
Bayer: Kaufempfehlung treibt an
Kursgewinne für die Bayer-Aktie (23,985 €)
See More Headlines

BAYN Stock Analysis - Frequently Asked Questions

Bayer Aktiengesellschaft's stock was trading at €19.31 at the start of the year. Since then, BAYN shares have increased by 28.1% and is now trading at €24.74.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include Hawkins (HWKN), NVIDIA (NVDA), Meta Platforms (META), Alibaba Group (BABA), Basf (BAS), Volkswagen (VOW3) and Bayerische Motoren Werke Aktiengesellschaft (BMW).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
ETR:BAYN
CIK
N/A
Fax
N/A
Employees
96,931
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
4.58
P/E Growth
36.39
Net Income
-$904.33 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$48.03 billion
Cash Flow
€4.32 per share
Price / Cash Flow
5.73
Book Value
€31.24 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
1,009,583,481
Free Float
N/A
Market Cap
$24.97 billion
Optionable
Not Optionable
Beta
0.97
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (ETR:BAYN) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners